HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$75.07
0.22 (0.29%)
▲
5d:
-3.29%
30d:
+13.11%
90d:
+33.48%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HAE shows positive signals but monitor for confirmation. Market pricing in 3.7% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: HAE shows positive signals but monitor for confirmation. Market pricing in 3.7% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$87.81
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$54.52
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $75.07, which is considered fair relative to its 30-day fair value range of $68.73 to $77.29. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.2) compared to its historical average (12.7). At these levels, the market is pricing in 3.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HAE is in a uptrend. Immediate support is located at $72.04, while resistance sits at $79.82.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $85.20 (+13.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HAE is in a uptrend. Immediate support is located at $72.04, while resistance sits at $79.82.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $85.20 (+13.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$68.73 -
$77.29
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($85.20)
- NEUTRAL: Market pricing in 3.7% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$68.73 -
$77.29
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$72.04
Resistance Level
$79.82
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.19
Wall Street Target
$85.20
(+13.5%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
28.4%
Profit Margin
7.3%
Valuation Premium vs History
+3.7% premium
PE vs Historical
14.2 vs 12.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.7%
(market-implied from PE analysis)
1-Year Target
$77.85
(+4%)
2-Year Target
$80.73
(+8%)
3-Year Target
$83.71
(+12%)
3-Yr Target (if PE normalizes)
(PE: 14→13)
PE COMPRESSION
$74.94
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.0%)
$141.35
(+88%)
Base:
(SPY PE: 14.2, Growth: 7.0%)
$92.07
(+23%)
Bear:
(PE: 12.1, Growth: 7.0%)
$78.26
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 36.51 | Current EPS (TTM): $2.05
Bull Case
$164.67
(+119%)
Analyst growth 100.0%, PE expands to 40.2
Base Case
$149.70
(+99%)
Market implied 100.0%, PE stable at 36.5
Bear Case
$50.90
(-32%)
Severe decline -20.0%, PE contracts to 31.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 5:05 PM ET
Data refreshes hourly during market hours. Next update: 6:05 PM
Data refreshes hourly during market hours. Next update: 6:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
